Press release
Global Nonalcoholic Steatohepatitis (NASH) Treatment Market US$ 19.8 Billion by 2025
https://www.ihealthcareanalyst.com/global-nonalcoholic-steatohepatitis-treatment-market/
No medicines have been approved to treat NAFLD and NASH. However, some studies suggest that pioglitazone (Actos), a medicine for type 2 diabetes, improves NASH in patients without diabetes. Targets for therapy are insulin resistance and oxidative stress. Antioxidants and antifibrotic agents, such as vitamin E and pentoxifylline, have not been approved for NASH/NAFLD treatment. Lifestyle changes are encouraged for patients with NASH, including reducing body weight, following a balanced diet, increasing physical activity, and avoiding alcohol. Lifestyle changes are critical in any attempt to reverse the course of NAFLD/NASH, and an evidence-based approved drug therapy for NAFLD/NASH is not available at present. The NASH therapies in clinical pipeline (phase II and III) include Aramchol, ARI 3037MO, BMS-986036, Cenicriviroc (TBR-652), Elafibranor (GF-505), Emricasan (IDN-6556), GR-MD-02, GS-4997, Liraglutide (Victoza/Saxenda), Obeticholic acid (OCA/Ocaliva), Simtuzumab (GS-6624), Tipelukast, and Volixibat (SHP 626).
Visit Nonalcoholic Steatohepatitis Treatment Market by Drug Type (Pioglitazone and Type 2 Diabetes Mellitus (T2DM) Medicines, Vitamin E, Others), Pipeline Analysis (Phase III Drugs - Aramchol (Arachidyl Amido Cholanoic Acid), Elafibranor (GFT505), Emricasan (IDN-6556, PF-03491390), Obeticholic Acid (OCA/Ocaliva), Simtuzumab (GS-6624), Others), and Phase I and II Drugs 2017-2025 at https://www.ihealthcareanalyst.com/global-nonalcoholic-steatohepatitis-treatment-market/
The global nonalcoholic steatohepatitis treatment market report provides market size (Revenue USD Million 2014 to 2025), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020). The global nonalcoholic steatohepatitis treatment market research report is segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global nonalcoholic steatohepatitis treatment market and included in this report are AstraZeneca plc, Conatus Pharmaceuticals, Galmed Pharmaceuticals, Genfit SA, Gilead Sciences Inc., Immuron Ltd., Intercept Pharmaceuticals Inc., Novartis, Pfizer, Sumitomo Dainippon Pharma, Tobira Therapeutics Inc., and Zydus Cadila.
1. Drug Type
1.1. Pioglitazone and Type 2 Diabetes Mellitus (T2DM) Medicines
1.2. Vitamin E
1.3. Others
2. Pipeline Analysis
2.1. Phase III Drugs
2.1.1. Aramchol (Arachidyl Amido Cholanoic Acid)
2.1.2. Elafibranor (GFT505)
2.1.3. Emricasan (IDN-6556, PF-03491390)
2.1.4. Obeticholic Acid (OCA/Ocaliva)
2.1.5. Simtuzumab (GS-6624)
2.1.6. Others
2.2. Phase I and II Drugs
3. Geography
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World
4. Company Profiles
4.1. AstraZeneca plc
4.2. Conatus Pharmaceuticals
4.3. Galmed Pharmaceuticals
4.4. Genfit Sa
4.5. Gilead Sciences Inc.
4.6. Immuron Ltd.
4.7. Intercept Pharmaceuticals, Inc.
4.8. Novartis
4.9. Pfizer
4.10. Sumitomo Dainippon Pharma
4.11. Tobira Therapeutics, Inc.
4.12. Zydus Cadila
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/nonalcoholic-steatohepatitis-treatment-market/
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare IT, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Nonalcoholic Steatohepatitis (NASH) Treatment Market US$ 19.8 Billion by 2025 here
News-ID: 724391 • Views: …
More Releases from iHealthcareAnalyst, Inc.
Global Amyotrophic Lateral Sclerosis Devices Market $19.5 Billion by 2029
The global market for amyotrophic lateral sclerosis devices or motor neuron disease devices anticipated to reach $19.5 billion by 2029, growing at a CAGR of 7.3% over the forecast period, driven by increasing incidence, rising geriatric population, lack of curative treatment, growing public awareness, and technological advancements in palliative care.
https://www.ihealthcareanalyst.com/global-amyotrophic-lateral-sclerosis-devices-market/
Amyotrophic lateral sclerosis or Lou Gehrig's disease or motor neuron disease (MND) is characterized by progressive degeneration of the motor nerve…
Global Blood Gas Monitoring Products Market Growing at CAGR of 6.2% to Reach $5. …
The global market for blood gas monitoring products is estimated to reach $5.5 billion by the end of 2025, expanding at a CAGR of 6.2% during the forecast period, supported by growing geriatric population, rising prevalence of chronic diseases, and technological advances.
The global blood gas monitoring devices market research report provides market size (Revenue US$ Million 2017 to 2025), market share analysis, growth trends and forecast (CAGR%, 2019 to 2025).…
Advances in Mobile Connectivity Services to Drive Telemedicine Technologies and …
According to a new market research report Telemedicine Technologies and Services Market 2015-2023 published by iHealthcareAnalyst, Inc., the global computer-aided detection market to reach US$ 73.2 Billion by 2023, expanding at a CAGR of 13.5% from 2018-2023.
Visit the Global Telemedicine Technologies and Services Market Analysis and Forecast 2018-2023 report at https://www.ihealthcareanalyst.com/report/telemedicine-technologies-services-market/
The global telemedicine technologies and services market newly published (updated 2018) report estimates the market size (US$ million 2015-2023)…
Global Internet Pharmacies Market to Cross US$ 100 Billion by 2023
The global internet pharmacies market is estimated to reach US$ 106 Billion by 2023, growing at a CAGR of 15.7% over the forecast period, driven by rising personal disposable income, lower prices, surge in internet penetration, stupendous growth of online retail market and a large number of online players entering the online healthcare product segment.
The major players are in a race to increase their share in the industry by…
More Releases for NASH
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their…
IQ4I Research published “Non-alcoholic steatohepataitis (NASH) Pipeline Analys …
“Non-alcoholic steatohepataitis (NASH) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report…
Growing Prevalence of NASH to Increase Adoption of Therapeutics
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
MarketResearchReports.biz has itemized the addition of a new market research report to its report repository. The research publication is titled, “Opportunity Analyzer: NASH - Opportunity Analysis and Forecasts to 2026.” The statistical surveying study is a watchful inspection of the general market…
OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026
First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. Progression of this condition to NASH dramatically increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma, and…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…
